The estimated Net Worth of Michael Fekete is at least $1.01 Million dollars as of 20 August 2021. Mr. Fekete owns over 10,000 units of SeaSpine Corp stock worth over $843,050 and over the last 9 years he sold SPNE stock worth over $0. In addition, he makes $165,000 as Independent Director at SeaSpine Corp.
Sign up
Mr. Fekete SPNE stock SEC Form 4 insiders trading
Michael has made over 3 trades of the SeaSpine Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of SPNE stock worth $148,000 on 20 August 2021.
The largest trade he's ever made was buying 10,000 units of SeaSpine Corp stock on 20 August 2021 worth over $148,000. On average, Michael trades about 1,185 units every 116 days since 2015. As of 20 August 2021 he still owns at least 88,370 units of SeaSpine Corp stock.
You can see the complete history of Mr. Fekete stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Fekete biography
Michael Paul Fekete serves as Independent Director of the Company. Mr. Fekete was a Managing Director and Head of West Coast Healthcare Investment Banking for Wells Fargo / Wachovia Securities (acquired by Wells Fargo in December 2008). From 1986 to 2005, Mr. Fekete worked as an investment banker at CIBC World Markets, Oppenheimer & Co., Inc., and L.F. Rothschild & Co., Inc., where he focused on clients in the medical device, pharmaceutical and biotechnology sectors. Mr. Fekete is a director of DFB Pharmaceuticals, LLC, a privately held company with operating and investing activities in the pharmaceutical sector. Mr. Fekete was a director of Sagent Pharmaceuticals, Inc. from July 2013 until it was acquired in August 2016 and Symetis SA from April 2011 until June 2016. Mr. Fekete earned his B.S. in business administration from The Pennsylvania State University.
What is the salary of Michael Fekete?
As the Independent Director of SeaSpine Corp, the total compensation of Michael Fekete at SeaSpine Corp is $165,000. There are 13 executives at SeaSpine Corp getting paid more, with Keith Valentine having the highest compensation of $1,840,570.
How old is Michael Fekete?
Michael Fekete is 55, he's been the Independent Director of SeaSpine Corp since 2015. There are 4 older and 17 younger executives at SeaSpine Corp. The oldest executive at SeaSpine Holdings Corp is Keith Bradley, 75, who is the Independent Director.
What's Michael Fekete's mailing address?
Michael's mailing address filed with the SEC is C/O SEASPINE HOLDINGS CORPORATION, 5770 ARMADA DRIVE, CARLSBAD, CA, 92008.
Insiders trading at SeaSpine Corp
Over the last 9 years, insiders at SeaSpine Corp have traded over $2,659,931 worth of SeaSpine Corp stock and bought 297,805 units worth $3,591,897 . The most active insiders traders include Stuart Essig, Richard E Caruso und Keith Valentine. On average, SeaSpine Corp executives and independent directors trade stock every 39 days with the average trade being worth of $151,762. The most recent stock trade was executed by John J. Winge on 1 January 2023, trading 4,868 units of SPNE stock currently worth $46,441.
What does SeaSpine Corp do?
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide.
What does SeaSpine Corp's logo look like?
Complete history of Mr. Fekete stock trades at SeaSpine Corp
SeaSpine Corp executives and stock owners
SeaSpine Corp executives and other stock owners filed with the SEC include:
-
Keith Valentine,
President, Chief Executive Officer, Director -
Keith C. Valentine,
Pres, CEO & Director -
John Bostjancic,
Chief Financial Officer, Senior Vice President, Treasurer -
Tyler Lipschultz,
Senior Vice President, Orthobiologics and Business Development -
Patrick Keran,
Vice President, General Counsel, Secretary -
John Winge,
Vice President of Sales -
John J. Bostjancic,
Sr. VP, CFO & Treasurer -
Patrick L. Keran,
Sr. VP, Gen. Counsel & Sec. -
Dr. Beau Standish P.Eng., Ph.D.,
Pres of Enabling Technologies -
Kimberly Commins-Tzoumakas,
Independent Director -
Renee Gaeta,
Independent Director -
Kirtley Stephenson,
Independent Non-Executive Chairman of the Board -
Stuart Essig,
Lead Independent Director -
Michael Fekete,
Independent Director -
Keith Bradley,
Independent Director -
John Henneman,
Independent Director -
Dennis Cirino,
Senior Vice President, Global Spinal Systems -
Hollis Winkler,
Sr. VP of HR -
Patrick L. Keran J.D.,
Sr. VP, Gen. Counsel & Sec. -
Dr. Frank Vizesi,
Chief Scientific Officer -
Shaeffer Bannigan,
Sr. Director of Product Devel. -
Paul Benny,
VP, Corp. Controller, Assistant Treasurer & Assistant Sec. -
Dr. Beau Standish Ph.D.,
Pres of Enabling Technologies -
Dennis L. Cirino,
Sr. VP of Global Spinal Systems -
Tyler P. Lipschultz,
Sr. VP of Orthobiologics & Bus. Devel. -
John J. Winge,
VP of Sales -
Carrie Mendivil,
Head of Investor Relations -
James M Sullivan,
Director -
Cheryl R Blanchard,
Director -
Brian D. Baker,
VP, Global Operations -
Richard E Caruso,
10% owner -
Shweta Maniar,
Director -
Life Sciences Corp Integra ...,
-
Beau Standish,
President, Enabling Tech -
Angela Steinway,
Director